A cytometric study of the red blood cells in Gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis

Cytometry Part B - Clinical Cytometry

Volumn 80 B, Issue 1, 2011, Pages 28-37

  Bratosin, Daniela ^a,b   Tissier, Jean Pierre ^c   Lapillonne, Hélène ^d   Hermine, Olivier ^e   De Villemeur, Thierry Billette ^f   Cotoraci, Coralia ^b   Montreuil, Jean ^g   Mignot, Cyril ^f  

^a National Institute for Biological Science Research and Development   (Romania)

^b VASILE GOLDIS WESTERN UNIVERSITY OF ARAD   (Romania)

^c CEMAGREF   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g UNIV LILLE   (France)

Author keywords

Calcein AM; CD47; Desialylation; Erythrocytes; Erythrophagocytosis; Erythroptosis; Flow cytometry; Gaucher disease; Phosphatidylserine exposure; Scanning electron microscopy; Terms

Indexed keywords

BIOLOGICAL MARKER; CALCEIN; CD47 ANTIGEN; GLYCOCONJUGATE; IMIGLUCERASE; PHOSPHATIDYLSERINE;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CELL MEMBRANE; CELL VIABILITY; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME REPLACEMENT; ERYTHROCYTE SHAPE; ERYTHROCYTE STRUCTURE; ERYTHROPHAGOCYTOSIS; FEMALE; FLOW CYTOMETRY; GAUCHER DISEASE; HUMAN; HUMAN CELL; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; PHAGOCYTOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SCHOOL CHILD; SENESCENCE; SIALYLATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78650830555     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20539     Document Type: Article

References (44)

1. Grabowski GA,. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008; 372: 1263 - 1271.
2. Montreuil J, Boulanger P, Houcke E,. Chromatographie sur papier des constituants glucidiques des cérébrosides s'un rate de Gaucher. Bull Soc Chim Biol 1953; 35: 1125 - 1127.
3. Bitton A, Etzell J, Grenert JP, Wang E,. Erythrophagocytosis in Gaucher cells. Arch Pathol Lab Med 2004; 128: 1191 - 1192.
4. Mignot C, Doummar D, Maire I, De Villemeur TB,. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006; 28: 39 - 48.
5. Sharpe LR, Ancliff P, Amrolia P, Gilmour KC, Vellodi A,. Type II Gaucher disease manifesting as haemophagocytic lymphohistiocytosis. J Inherit Metab Dis Short Report 2009; 157: In press [Epub].
6. Gielchinsky Y, Elstein D, Hadas Halpern I, Lahad A, Abrahamov A, Zimran A,. Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease. Br J Haematol 1999; 106: 812 - 816.
7. Lee RE, Balcerzak SP, Westerman MP,. Gaucher's disease. A morphologic study and measurements of iron metabolism. Am J Med 1967; 42: 891 - 898.
8. Pennelli N, Scaravilli F, Zacchello F,. The morphogenesis of Gaucher cells investigated by electron microscopy. Blood 1969; 34: 331 - 347.
9. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD,. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004; 122: 359 - 369.
10. Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM,. Pathologic gene expression in Gaucher disease: Up regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000; 96: 1969 - 1978.
11. Moskwa P, Palicz A, Paclet MH, Dagher MC, Erdos M, Marodi L, Ligeti E,. Glucocerebroside inhibits NADPH oxidase activation in cell free system. Biochim Biophys Acta 2004; 1688: 197 - 203.
12. Marodi L, Kaposzta R, Toth J, Laszlo A,. Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy. Blood 1995; 86: 4645 - 4649.
13. Nilsson O, Hakansson G, Dreborg S, Groth CG, Svennerholm L,. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clin Genet 1982; 22: 274 - 279.
14. Bax BE, Richfield L, Bain MD, Mehta AB, Chalmers RA, Rampling MW,. Haemorheology in Gaucher disease. Eur J Haematol 2005; 75: 252 - 258.
15. Zimran A, Bashkin A, Elstein D, Rudensky B, Rotstein R, Rozenblat M, et al. Rheological determinants in patients with Gaucher disease and internal inflammation. Am J Hematol 2004; 75: 190 - 194.
16. Adar T, Ben-Ami R, Elstein D, Zimran A, Berliner S, Yedgar S, Barshtein G,. Aggregation of red blood cells in patients with Gaucher disease. Br J Haematol 2006; 134: 432 - 437.
17. Tibblin E, Dreborg S, Erikson A, Hakansson G, Svennerholm L,. Hematological findings in the Norrbottnian type of Gaucher disease. Eur J Pediatr 1982; 139: 187 - 191.
18. Bratosin D, Mazurier J, Tissier JP, Estaquier J, Huart JJ, Ameisen JC, Aminoff D, Montreuil J,. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie 1998; 80: 173 - 195.
19. Bratosin D, Estaquier J, Petit F, Arnoult D, Quatannens B, Tissier JP, Slomianny C, Sartiaux C, Alonso C, Huart JJ, Montreuil J, Ameisen JC,. Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death Differ 2001; 8: 1143 - 1156.
20. Berg CP, Engels IH, Rothbart A, Lauber K, Renz A, Schlosser SF, Schultze Osthoff K, Wesselborg S,. Human mature red blood cells express caspase 3 and caspase 8, but are devoid of mitochondrial regulators of apoptosis. Cell Death Differ 2001; 8: 1197 - 206.
21. Bratosin D, Tcacenco L, Sidoroff M, Cotoraci C, Slomianny C, Estaquier J, Montreuil J,. Active caspases 8 and -3 in circulating human erythrocytes purified on immobilized annexin V: a cytometric demonstration. Cytometry A 2009; 75: 236 - 244.
22. Daugas E, Cande C, Kroemer G,. Erythrocytes: Death of a mummy. Cell Death Differ 2001; 8: 1131 - 1133.
23. Khandelwal S, van Rooijen N, Saxena RK,. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 2007; 47: 1725 - 1732.
24. Mohandas N, Gallagher PG,. Red cell membrane: Past, present, and future. Blood 2008; 112: 3939 - 3948.
25. Bratosin D, Mazurier J, Slomianny C, Aminoff D, Montreuil J,. Molecular mechanisms of erythrophagocytosis: Flow cytometric quantitation of in vitro erythrocyte phagocytosis by macrophages. Cytometry 1997; 30: 269 - 274.
26. Bratosin D, Mitrofan L, Palii C, Estaquier J, Montreuil J,. Novel fluorescence assay using calcein AM for the determination of human erythrocyte viability and aging. Cytometry A 2005; 66: 78 - 84.
27. Bratosin D, Mazurier J, Debray H, Lecocq M, Boilly B, Alonso C, Moisei M, Motas C, Montreuil J,. Flow cytofluorimetric analysis of young and senescent human erythrocytes probed with lectins. Evidence that sialic acids control their life span. Glycoconj J 1995; 12: 258 - 267.
28. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP,. Role of CD47 as a marker of self on red blood cells. Science 2000; 288: 2051 - 2054.
29. Hughes D, Cappellini MD, Berger M, Van Droogenbroeck J, de Fost M, Janic D, Marinakis T, Rosenbaum H, Villarubia J, Zhukovskaya E, Hollak C,. Recommendations for the management of the haematological and onco haematological aspects of Gaucher disease. Br J Haematol 2007; 138: 676 - 686.
30. Bull BS, Kuhn IN,. The production of schistocytes by fibrin strands (a scanning electron microscope study). Blood 1970; 35: 104 - 111.
31. Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH,. Coagulation abnormalities in type 1 Gaucher disease are due to low grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 1997; 96: 470 - 476.
32. Deghady A, Marzouk I, El Shayeb A, Wali Y,. Coagulation abnormalities in type 1 Gaucher disease in children. Pediatr Hematol Oncol 2006; 23: 411 - 417.
33. Uluhan A, Paydas S, Seyrek E, Tuncer I, Cosar E, Sahin B,. A case of late onset Gaucher disease with severe pulmonary involvement and concurrent tuberculosis. J Islam Acad Sci 1993; 6: 63 - 66.
34. Elshimali Y, Ganjian S,. Gaucher's disease in a 72 year old man: Case report and review of the literature. Internet J Pathol 2007; 6 (1).
35. Dibella NJ, Silverstein MN, Hoagland HC,. Effect of splenectomy on teardrop shaped erythrocytes in agnogenic myeloid metaplasia. Arch Intern Med 1977; 137: 380 - 381.
36. Leong C, Cheong S,. Trduction of teaar drop poikilocytes in a case of myelofibrosis following splenectomy. Med Health 2006; 1: 81 - 84.
37. Farolino DL, Rustagi PK, Currie MS, Doeblin TD, Logue GL,. Teardrop shaped red cells in autoimmune hemolytic anemia. Am J Hematol 1986; 21: 415 - 418.
38. Erikson A, Astrom M, Mansson JE,. Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. Neuropediatrics 1995; 26: 203 - 207.
39. Westerlund B, Slotte JP,. How the molecular features of glycosphingolipids affect domain formation in fluid membranes. Biochim Biophys Acta 2009; 1788: 194 - 201.
40. Salzer U, Zhu R, Luten M, Isobe H, Pastushenko V, Perkmann T, Hinterdorfer P, Bosman GJ,. Vesicles generated during storage of red cells are rich in the lipid raft marker stomatin. Transfusion 2008; 48: 451 - 462.
41. Hagerstrand H, Mrowczynska L, Salzer U, Prohaska R, Michelsen KA, Kralj Iglic V, Iglic A,. Curvature dependent lateral distribution of raft markers in the human erythrocyte membrane. Mol Membr Biol 2006; 23: 277 - 288.
42. Hein LK, Duplock S, Hopwood JJ, Fuller M,. Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res 2008; 49: 1725 - 1734.
43. Rogowski O, Shapira I, Zimran A, Zeltser D, Elstein D, Attias D, Bashkin A, Berliner S,. Automated system to detect low grade underlying inflammatory profile: Gaucher disease as a model. Blood Cells Mol Dis 2005; 34: 26 - 29.
44. Adar T, Ben Ami R, Elstein D, Zimran P, Berliner S, Yedgar S, Barshtein G,. Increased red blood cell aggregation in patients with Gaucher disease is non inflammatory. Clin Hemorheol Microcirc 2008; 40: 113 - 118.